aTYR PHARMA
NASDAQ: ATYRSan Diego, US · Delaware corporation · 6 known investors
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
Founders & leadership
PS
JD
John D. MendleinExecutive
DW
David WeinerExecutive
FC
Frederic ChereauExecutive
Board
AN
Amir Nashatin𝕏Non-Management DirectorEntrepreneur partner at Polaris Partners focused on healthcare investing and portfolio company executive roles
AS
Akkaraju SrinivasNon-Management Director
JC
James C. BlairNon-Management Director
JK
EP
Ed PenhoetNon-Management Director
KF
Kathryn FalbergNon-Management Director
Investors · 6
Reported raises · per SEC filings
Form D private placements$122.1M disclosed across 2 rounds · 2015–2017
▶$45.8MraisedSep 2017 · 11 investors · BiotechnologyRule 506(b)
▶$45.8MraisedSep 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. HatfieldDirector
- John D. MendleinExecutive Officer, Director
- John T. BlakeExecutive Officer
- Amir H. Nashat, Sc.D.Director
- Sanjay S. ShuklaExecutive Officer
- Mark GoldbergDirector
- Sanuj K. RavindranExecutive Officer
- Nancy D. KruegerExecutive Officer
- John K. ClarkeDirector
- Paul SchimmelDirector
- Srini AkkarajuDirector
- Timothy P. CoughlinDirector
- James C. BlairDirector
- Offering amount
- $45.8M
- Amount sold
- $45.8M
- Sales commissions
- $2.8M
- Placement agents
- Piper Jaffray & Co.
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$76.3MraisedApr 2015 · 42 investors · BiotechnologyRule 506(b)
▶$76.3MraisedApr 2015 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amir NashatDirector
- Paul SchimmelDirector
- Akkaraju SrinivasDirector
- John D. MendleinExecutive Officer, Director
- David WeinerExecutive Officer
- Ed PenhoetDirector
- Frederic ChereauExecutive Officer
- Kathryn FalbergDirector
- James C. BlairDirector
- John K. ClarkeDirector
- Offering amount
- $76.3M
- Amount sold
- $76.3M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Seeking Alpha43 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView42 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood38 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TipRanks36 shared keywordsFinancial analysis and stock research platform.
StockTwits36 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Public35 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies competing with aTYR PHARMA for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does aTYR PHARMA do?
- aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
- Who founded aTYR PHARMA?
- aTYR PHARMA was founded by Paul Schimmel.
- Who are aTYR PHARMA's investors?
- aTYR PHARMA's investors include Cardinal Partners, EcoR1 Capital, Sofinnova Ventures, Domain Partners, Polaris Partners, Samsara BioCapital.
- How much funding has aTYR PHARMA raised?
- aTYR PHARMA has disclosed $122.1M raised across 2 rounds.
- Where is aTYR PHARMA headquartered?
- aTYR PHARMA is headquartered in San Diego, US.